<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/CAE6064D-E654-468D-A15C-0AFC93FFDB6B"><gtr:id>CAE6064D-E654-468D-A15C-0AFC93FFDB6B</gtr:id><gtr:name>Domainex Limited</gtr:name><gtr:address><gtr:line1>London Biosciences Innovation Centre
2 Royal College Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 0NH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CAE6064D-E654-468D-A15C-0AFC93FFDB6B" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>CAE6064D-E654-468D-A15C-0AFC93FFDB6B</gtr:id><gtr:name>Domainex Limited</gtr:name><gtr:address><gtr:line1>London Biosciences Innovation Centre
2 Royal College Street</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>NW1 0NH</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>250000.0</gtr:offerGrant><gtr:projectCost>569790.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5883F54E-4B53-4D94-A35E-94E888E18583"><gtr:id>5883F54E-4B53-4D94-A35E-94E888E18583</gtr:id><gtr:firstName>Tony</gtr:firstName><gtr:surname>Signorini</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720028"><gtr:id>135CDB28-8EDC-4693-B15A-964E3B65E6AF</gtr:id><gtr:title>A new drug targeting the enzymes TBK1 and IKKe for the treatment of cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720028</gtr:grantReference><gtr:abstractText>Our aim is to invent a new drug for the treatment of several common cancers through
inhibition of the enzymes IKKe and/or TBK1. Recent academic research has shown that
blocking these closely-related protein kinases will stop cancer cells growing, and force them
to die. Furthermore these enzymes are important in some inflamatory diseases, obesity, and
Type 2 diabetes.
Our initial markets are breast and ovarian cancers. Breast cancer is the most common cancer
in women ? every year it affects over a million women worldwide - and is the leading cause of
death for women aged 40-44. The five-year survival rate for Stage V cancer patients
(advanced disease progression) is just 16%. Ovarian cancer is rarely diagnosed in its early
stages and is usually quite advanced by the time diagnosis is made, resulting in poor
prognoses. The five-year survival rate for all stages is only 35% to 38%.
An IKKe/TBK1 inhibitor would have a significant impact on patients with these cancers,
leading to better quality of life, and improved five-year survival rates. This drug will also
reduce healthcare costs because unlike many existing drugs, this new treatment will be
designed to be taken as a pill at home, rather than by infusion in hospital.
The objective of this programme is to identify a candidate drug that is effective in disease
models and would be orally well-absorbed by humans. The subsequent commercialisation of
this new drug would be through a partnership with a large pharmaceutical company with the
resources to take on this expensive stage of product development.
Domainex is presently a leader in this field. The funding of this proposal will allow
Domainex to recruit a number of scientists ? preserving highly-skilled drug discovery jobs in
the UK. Given recent trends in the pharmaceutical industry it is very likely that the future of
drug research in this country will be based largely upon the success and growth of
biotechnology companies such as Domainex.</gtr:abstractText><gtr:fund><gtr:end>2013-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2011-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>250000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720028</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>